MedTrace Logo

Treating Schizophrenia by Correcting Abnormal Brain Development

NCT00179465 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-01-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease.

This study is funded by the National Institutes of Health.

Conditions

Interventions

DRUG

Tiagabine

Up to 36 mg daily

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • T.-U. Wilson Woo, M.D., Ph.D. · Beth Israel Deaconess Medical Center, Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00179465 on ClinicalTrials.gov